HBV cure: why, how, when? - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue Current Opinion in Virology Année : 2016

HBV cure: why, how, when?

Résumé

Current HBV treatments control replication and liver disease progression in the vast majority of treated patients. However, HBV patients often require lifelong therapies due to the persistence of transcriptionally active viral cccDNA mini-chromosome in the nucleus, which is not directly targeted by current antiviral therapies. A true complete cure of HBV would require clearance of intranuclear cccDNA from all infected hepatocytes. An intermediate but still relevant step forward that would allow treatment cessation would be reaching a functional cure, equivalent to resolved acute infection, with a durable HBsAg loss+/-anti-HBs seroconversion, undetectable serum DNA and persistence of cccDNA in a transcriptionally inactive status. Recent advances in technologies and pharmaceutical sciences, including the cloning of the mayor HBV receptor (i.e. the NTCP transporter) and the development in vitro HBV infection models, have heralded a new horizon of innovative antiviral and immune-therapeutic approaches
Fichier non déposé

Dates et versions

hal-01797257 , version 1 (22-05-2018)

Identifiants

Citer

M. Levrero, B. Testoni, F. Zoulim. HBV cure: why, how, when?. Current Opinion in Virology, 2016, 18, pp.135-143. ⟨10.1016/j.coviro.2016.06.003⟩. ⟨hal-01797257⟩
13 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More